| Autor: |
Breen CT; Christopher T. Breen is a medical student at Yale School of Medicine. He received an A.B. in Politics from Princeton University. David A. Fiellin, M.D., is a Professor of Medicine, Emergency Medicine and Public Health at Yale where he directs the Program in Addiction Medicine. His research is focused on implementing addiction treatment in general medical settings., Fiellin DA; Christopher T. Breen is a medical student at Yale School of Medicine. He received an A.B. in Politics from Princeton University. David A. Fiellin, M.D., is a Professor of Medicine, Emergency Medicine and Public Health at Yale where he directs the Program in Addiction Medicine. His research is focused on implementing addiction treatment in general medical settings. |
| Jazyk: |
angličtina |
| Zdroj: |
The Journal of law, medicine & ethics : a journal of the American Society of Law, Medicine & Ethics [J Law Med Ethics] 2018 Jun; Vol. 46 (2), pp. 272-278. |
| DOI: |
10.1177/1073110518782934 |
| Abstrakt: |
Buprenorphine is a form of opioid agonist treatment that has been demonstrated to be an effective medication for opioid addiction. It is available in different formulations and marketed under various trade names, including commonly as a buprenorphine/naloxone combination. This paper provides an overview of existing literature on the supply of buprenorphine treatment, the ability of people to access treatment with buprenorphine, and the quality of treatment received. We argue that better data for each of these aspects of treatment could inform policy to expand effective treatment with buprenorphine, and we suggest steps to obtain and act on such data. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
